Biotech News

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Aptevo Therapeutics (APVO)Aptevo Therapeutics2026-06-25 13:46 ESTClinical readout

89% of evaluable mipletamig patients achieve remission in combination therapy for frontline AML across two trials Introduces first trispecific molecules, APVO451 and APVO452, advancing therapies designed to overcome immune suppression in certain solid tumors Both molecules leverage Aptevo's unique

Open original release

Related news

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

APVOAptevo Therapeutics2026-06-25 13:46 EST

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

APVOAptevo Therapeutics2026-06-25 13:46 EST

Aptevo to Participate in March 2026 Conferences

View all latest news

Aptevo Therapeutics

Aptevo Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

APVOAptevo Therapeutics2026-06-26 07:17 EST

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer

APVOAptevo Therapeutics2026-06-26 07:17 EST

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

APVOAptevo Therapeutics2026-06-26 07:17 EST

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

APVOAptevo Therapeutics2026-06-26 07:17 EST

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

APVOAptevo Therapeutics2026-06-26 07:17 EST

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States